Tourmaline Bio Net Worth
Tourmaline Bio Net Worth Breakdown | TRML |
Tourmaline Bio Net Worth Analysis
Tourmaline Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Tourmaline Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Tourmaline Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Tourmaline Bio's net worth analysis. One common approach is to calculate Tourmaline Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Tourmaline Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Tourmaline Bio's net worth. This approach calculates the present value of Tourmaline Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Tourmaline Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Tourmaline Bio's net worth. This involves comparing Tourmaline Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Tourmaline Bio's net worth relative to its peers.
To determine if Tourmaline Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tourmaline Bio's net worth research are outlined below:
| Tourmaline Bio appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (42.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tourmaline Bio generates negative cash flow from operations | |
| Tourmaline Bio has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and ... |
Tourmaline Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tourmaline Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tourmaline Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Tourmaline Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 650.3 M.Market Cap |
|
Project Tourmaline Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.21) | (0.20) |
When accessing Tourmaline Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Tourmaline Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tourmaline Bio's profitability and make more informed investment decisions.
Evaluate Tourmaline Bio's management efficiency
Tourmaline Bio has return on total asset (ROA) of (0.2382) % which means that it has lost $0.2382 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3182) %, meaning that it created substantial loss on money invested by shareholders. Tourmaline Bio's management efficiency ratios could be used to measure how well Tourmaline Bio manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.21. The value of Return On Capital Employed is expected to slide to -0.23. At this time, Tourmaline Bio's Other Assets are quite stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 43.19 | 60.09 | |
| Tangible Book Value Per Share | 43.19 | 60.09 | |
| Enterprise Value Over EBITDA | 0.35 | 0.37 | |
| Price Book Value Ratio | 0.61 | 0.64 | |
| Enterprise Value Multiple | 0.35 | 0.37 | |
| Price Fair Value | 0.61 | 0.64 | |
| Enterprise Value | 179.7 M | 159.7 M |
Tourmaline Bio has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Return On Equity (0.32) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tourmaline Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tourmaline Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tourmaline Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kulkarni Sandeep Chidambar over three months ago Acquisition by Kulkarni Sandeep Chidambar of 5221 shares of Tourmaline Bio at 13.79 subject to Rule 16b-3 | ||
Robinson Ryan F. over three months ago Acquisition by Robinson Ryan F. of 76400 shares of Tourmaline Bio at 14.21 subject to Rule 16b-3 | ||
Mcdade Mark over six months ago Purchase by Mcdade Mark of 100000 shares of Tourmaline Bio | ||
Kulkarni Sandeep Chidambar over a year ago Purchase by Kulkarni Sandeep Chidambar of 4000 shares of Tourmaline Bio | ||
Kulkarni Sandeep Chidambar over a year ago Purchase by Kulkarni Sandeep Chidambar of 4650 shares of Tourmaline Bio | ||
Kulkarni Sandeep Chidambar over a year ago Acquisition by Kulkarni Sandeep Chidambar of 716085 shares of Tourmaline Bio subject to Rule 16b-3 |
Tourmaline Bio Corporate Filings
8K | 10th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 22nd of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 19th of April 2024 Other Reports | ViewVerify |
Tourmaline Bio Earnings per Share Projection vs Actual
Tourmaline Bio Corporate Management
| Susan Jones | Chief Officer | Profile | |
| Kimberly Piorkowski | Culture People | Profile | |
| Bradford JD | General Officer | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Emil MD | Senior Research | Profile | |
| Yung MD | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tourmaline Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tourmaline Bio. If investors know Tourmaline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tourmaline Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.49) | Return On Assets (0.24) | Return On Equity (0.32) |
The market value of Tourmaline Bio is measured differently than its book value, which is the value of Tourmaline that is recorded on the company's balance sheet. Investors also form their own opinion of Tourmaline Bio's value that differs from its market value or its book value, called intrinsic value, which is Tourmaline Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tourmaline Bio's market value can be influenced by many factors that don't directly affect Tourmaline Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tourmaline Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tourmaline Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tourmaline Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.